Submit Deal

BIOVERATIV INC

Summary

Bioverativ is an American multinational biotechnology that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 8.49 B

Avg. Deal Size£ 4.24 B

Market Context

Senior Management

John G. Cox
CEO
John Greene
CFO
Brian M. Posner
Chairman

Sort

23 May 2017|United States|Biotechnology

Target: THE NORTH THERAPEUTICS

Bidder: BIOVERATIV INC

1 Service Providers

1 Target

2 Dealmakers

2 Target

£ 635 M

Value

22 Jan 2018|United States|Biotechnology

Target: BIOVERATIV INC

Bidder: SANOFI SA

11 Service Providers

7 Target | 4 Bidder

45 Dealmakers

13 Target | 32 Bidder

£ 7.85 B

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy